Sourena Nadji

The company's CO-founder, Dr. Sourena Nadji, currently serves as the Chief Scientific Officer and Vice President of process development. He is also the Founder and CEO of PharmaRen LLC, engaged in developing complex synthetic, injectable Generic Drugs. He has over 35 years of experience in synthetic chemistry and managing inject-able generic drug development from early research and development through DMF registration. Before founding PharmaRen, he held the R&D; Director position at Reliable Pharmaceutical Co., overseeing target identification and prioritization, management of R&D;, and grant writing. In this position, he successfully developed novel chemical processes, backed by process patents, for manufacturing Generics at competitive costs. Several generic drugs developed by his groups, such as Fludarabine, Floxuridine, Cladribine, Dexmedetomidine, and Chlorothiazide, are already in the US market, and some others, such as Regadenoson, Lacosamide, Plerixafor, and Ibutilide are yet to be marketed. Sourena received a bachelor's degree in Chemistry from the Pahlavi University (Shiraz, IRAN), an MSc. and Ph.D. in Heterocyclic chemistry from East Anglia University (Norwich, UK). He conducted post-doctoral research in Chemistry and chemical biology at Yale University, Brookline Polytechnic University, Southern Illinois University, and Washington University in Saint Louis. In 2018, He founded heparinbuildingblocks.com to offer heparin building blocks to the scientific community around the globe at a cost price to help expand the research in heparan sulfate biology.